ELIEM THERAPEUTICS INC (ELYM) Stock Price, Quote, News and Overview
NASDAQ:ELYM - Nasdaq - US28658R1068 - Common Stock - Currency: USD
ELYM Quote, Performance and Key Statistics
5.11
-0.05 (-0.97%)
The current stock price of ELYM is 5.11 USD. In the past month the price decreased by -29.42%. In the past year, price increased by 95.04%.
ELYM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ELYM
Company Profile
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wilmington, Delaware and currently employs 9 full-time employees. The company went IPO on 2021-08-10. The company is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company also focuses on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing TNT119, an anti-CD19 antibody designed for a range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. Its clinical-stage program, ETX-155, is an investigational, oral, neuroactive steroid NCE that is designed to act as a positive allosteric modulator (PAM) of the GABAA receptor (GABAAR). The GABAA PAM neuroactive steroid class has been clinically validated in depression and epilepsy. ETX-155 for use in multiple disorders of high unmet need, including major depressive disorder (MDD) and focal onset seizures (FOS).
Company Info
ELIEM THERAPEUTICS INC
2801 Centerville Road 1St Floor, Pmb #117
Wilmington DELAWARE US
CEO: Robert Azelby
Employees: 10
Company Website: https://eliemtx.com/
Phone: 18773543689
ELIEM THERAPEUTICS INC / ELYM FAQ
What is the stock price of ELIEM THERAPEUTICS INC today?
The current stock price of ELYM is 5.11 USD. The price decreased by -0.97% in the last trading session.
What is the ticker symbol for ELIEM THERAPEUTICS INC stock?
The exchange symbol of ELIEM THERAPEUTICS INC is ELYM and it is listed on the Nasdaq exchange.
On which exchange is ELYM stock listed?
ELYM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ELIEM THERAPEUTICS INC stock?
6 analysts have analysed ELYM and the average price target is 4.59 USD. This implies a price decrease of -10.18% is expected in the next year compared to the current price of 5.11. Check the ELIEM THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ELIEM THERAPEUTICS INC worth?
ELIEM THERAPEUTICS INC (ELYM) has a market capitalization of 342.68M USD. This makes ELYM a Small Cap stock.
How many employees does ELIEM THERAPEUTICS INC have?
ELIEM THERAPEUTICS INC (ELYM) currently has 10 employees.
What are the support and resistance levels for ELIEM THERAPEUTICS INC (ELYM) stock?
ELIEM THERAPEUTICS INC (ELYM) has a support level at 5.04 and a resistance level at 8.19. Check the full technical report for a detailed analysis of ELYM support and resistance levels.
Should I buy ELIEM THERAPEUTICS INC (ELYM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ELYM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ELYM, evaluating the profitability, health, valuation and growth aspects
- ELIEM THERAPEUTICS INC (ELYM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ELIEM THERAPEUTICS INC (ELYM) Sales and EPS estimates to see what analysts future expectations are.
- ELIEM THERAPEUTICS INC (ELYM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ELIEM THERAPEUTICS INC (ELYM) Insider and Institutional Ownership to learn about the owners and their transactions.
- ELIEM THERAPEUTICS INC (ELYM) Stock Chart to make your own analysis
- ELIEM THERAPEUTICS INC (ELYM) Latest news and press-releases to stay up to date.
Does ELIEM THERAPEUTICS INC (ELYM) stock pay dividends?
ELYM does not pay a dividend.
What is the Price/Earnings (PE) ratio of ELIEM THERAPEUTICS INC (ELYM)?
ELIEM THERAPEUTICS INC (ELYM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.15).
ELYM Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ELYM. When comparing the yearly performance of all stocks, ELYM is one of the better performing stocks in the market, outperforming 88.48% of all stocks.
ELYM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ELYM. While ELYM has a great health rating, there are worries on its profitability.
ELYM Financial Highlights
Over the last trailing twelve months ELYM reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS decreased by -27.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.4% | ||
| ROE | -28.88% | ||
| Debt/Equity | 0 |
ELYM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ELYM. The Buy consensus is the average rating of analysts ratings from 6 analysts.